CGC vs CRON: How Canopy Growth Corporation and Cronos Group Compare (2026)
Last updated July 2026
Short answer
CRON is the larger of the two ($1.07B market cap): the incumbent the market prices for continued execution (-71.38x forward earnings, beta 1.24). CGC is the smaller challenger ($390.30M), priced similarly on forward earnings (-7.23x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
CGC vs CRON: the tie-breaker metrics
Same yardstick, side by side (as of July 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | CGC | CRON | What it tells you |
|---|---|---|---|
| Market cap | $390.30M | $1.07B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | -7.23 | -71.38 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 2.41 | 1.24 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 2% of range | 62% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 0.74 | 1.00 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how CGC and CRON affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CGC and CRON share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CGC and CRON exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Canopy Growth Corporation (CGC) do?
Canopy Growth Corporation is one of Canada's largest cannabis companies, based in Smiths Falls, Ontario. It sells recreational (adult-use) and medical cannabis in Canada, exports medical cannabis to international markets in Europe and Australia, and owns Storz & Bickel, a maker of premium vaporizer devices. Its revenue comes mainly from selling cannabis flower, pre-rolls, vapes, edibles, and beverages under brands like Tweed and Doja, plus device sales. In fiscal 2026 the company completed its acquisition of MTL Cannabis, a move it says makes it Canada's leading medical-cannabis provider by revenue, and reported that its core cannabis business returned to growth after years of contraction.
What does Cronos Group (CRON) do?
Cronos Group Inc. is a Canada-based, globally focused cannabis company that concentrates on building consumer brands and monetizing intellectual property rather than owning the full, capital-intensive cultivation chain. Its portfolio spans Spinach (a top-selling recreational brand in Canada across edibles, vapes, and flower), PEACE NATURALS (a global medical brand distributed in Canada, Israel, Germany, and the UK), the luxury CBD line Lord Jones, and LIT. Much of the long-running investment story traces to 2019, when tobacco giant Altria invested roughly CA$2.4 billion for a large equity stake, which today sits near 41% ownership. That deal left Cronos with an unusually strong, debt-free balance sheet holding on the order of $800 million in cash and equivalents, a figure large relative to the company's own market value.
CGC vs CRON: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- CGC drivers: Core cannabis business back to growth; MTL Cannabis and medical leadership.
- CRON drivers: Fortress balance sheet and Altria backing; Brand-led, asset-light model.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The central risk is that Canopy is still unprofitable in a brutally competitive industry. For CRON, the biggest risk is regulatory: cannabis remains federally illegal in the US, and reform timelines (rescheduling, SAFE banking, legalization) have slipped repeatedly, so much of the bull case depends on events Cronos cannot control.
CGC or CRON: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CGC if you believe its drivers more; CRON if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CGC and CRON guides.
CGC vs CRON: the full fundamentals
CGC. These figures are qualitative and tied to the asOf date; verify live numbers before acting. Because Canopy is unprofitable, standard earnings multiples do not apply, and the stock trades on revenue trajectory, cash runway, and expectations for cannabis reform rather than on profits. Reported financials are also in Canadian dollars, so US-dollar figures depend on exchange rates. Treat any single quarter with caution: cannabis results swing on pricing, one-time charges, and restructuring.
CRON. These figures are approximate, tied to the asOf date, and drawn from 2025 into 2026 reporting; verify live numbers before acting. For a cash-heavy, small-revenue cannabis name, standard earnings multiples are of limited use because so much of the value sits in cash and in an option on policy change rather than in current profits. Compare the market cap to net cash and watch capital allocation as closely as revenue.
Headline figures (approximate, Jul 2026): CGC shows revenue trend (fy2026) Modest annual growth (roughly mid-single-digit percent), the first sustained return to growth after years of contraction, growth drivers Double-digit gains in Canadian adult-use, Canadian medical, and international cannabis; device sales (Storz & Bickel) were softer, profitability Still net-loss-making, but fiscal 2026 net loss from continuing operations narrowed roughly by half versus the prior year, balance sheet Shifted to a net-cash position after a January 2026 recapitalization, reducing near-term financing risk; CRON shows revenue scale Small but growing; net revenue was a record ~$36 million in Q3 2025, driven by Canadian edibles and international medical sales, balance sheet Debt-free with a large cash position (roughly $800 million in cash and equivalents as reported through 2025), sizable relative to market value, altria ownership Altria holds an approximately 41% equity stake, dating to its ~CA$2.4 billion 2019 investment, profitability Historically loss-making at the operating level; results are volatile and heavily influenced by non-cash items and investment gains or losses.
The bottom line: CGC vs CRON
CGC and CRON are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CGC and CRON exposure against your real portfolio. It is not an investment adviser.
Investing in Canopy Growth Corporation with AI
Connect the broker you already use and ask Walnut's AI how CGC fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between CGC and CRON?
+
Canopy Growth Corporation is one of Canada's largest cannabis companies, based in Smiths Falls, Ontario. Cronos Group Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is CGC or CRON the better stock?
+
Neither is universally better. CRON is the larger incumbent; CGC is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, CGC or CRON?
+
On forward P/E (as of July 2026), CGC trades at -7.23x and CRON at -71.38x, so CRON is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both CGC and CRON?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of CGC vs CRON?
+
CGC: The central risk is that Canopy is still unprofitable in a brutally competitive industry. Canadian adult-use cannabis suffers from oversupply and price compression, which squeezes margins even as volumes grow. The company has a long history of large writedowns (BioSteel, Wana, and others) and heavy share dilution, so existing shareholders have repeatedly been diluted to fund losses. Its US upside through Canopy USA depends on federal reform that has been promised for years without arriving, and remains outside the company's control. Canopy also restated prior-period financials for non-cash technical errors tied to certain US-dollar share-settled warrants. As a small-cap cannabis stock, CGC is highly volatile and sensitive to sentiment, financing conditions, and regulatory headlines, with no guarantee the turnaround reaches sustained profitability. CRON: The biggest risk is regulatory: cannabis remains federally illegal in the US, and reform timelines (rescheduling, SAFE banking, legalization) have slipped repeatedly, so much of the bull case depends on events Cronos cannot control. The operating business is still small and only recently profitable in places, so results can disappoint even in a good policy environment. Canada's recreational market is oversupplied and price-competitive, pressuring margins. International expansion adds execution, currency, and integration risk, including the CanAdelaar deal. The Altria stake is a double edge: it provides support but also concentrates influence and ties Cronos's fate partly to Altria's strategy. Finally, because so much value is the cash pile, capital-allocation decisions (buybacks, M&A, or a large cash-burning bet) matter enormously to whether that balance sheet compounds or erodes.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell CGC or CRON; figures are approximate and dated (as of July 2026). Verify current data before investing.